Skip to main content
. 2022 Apr 5;29(10):1982–1995. doi: 10.1038/s41418-022-00990-5

Fig. 6. PRMT4 disruption protects against DOX-induced ferroptosis in vivo.

Fig. 6

AAV-shPRMT4 or AAV-shNC were applied via tail vein injection, 2 weeks later, DOX was injected intraperitoneally, then hearts were harvested for analysis on day 7. a Representative DHE staining images were shown; b Relative ROS intensity was statistically analyzed, *P < 0.001, #P < 0.001; c-e Quantitative analysis of GSH level (c, *P < 0.001, #P < 0.01), MDA level (d, *P < 0.001, #P < 0.01), and GPX4 activity (e, *P < 0.001, #P < 0.001); f Representative western blots of PRMT4, NCOA4, and GPX4 were shown; g-i Quantitative analysis of the protein level of PRMT4 (g, *P < 0.001, #P < 0.01, $P < 0.001), NCOA4 (h, *P < 0.001, #P < 0.001), and GPX4 (i, *P < 0.05, #P < 0.01).